hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06323070, orgStudyIdInfo id: HS-2023-0281, briefTitle: Effects of Watermelon or Low-fat Cookie Consumption on Wellness, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: San Diego State University, class: OTHER, descriptionModule briefSummary: The objective of the proposed research is to determine the effects of fresh watermelon consumption on physiological indicators of wellness regarding sexual, skin and gut health in adults., conditionsModule conditions: Overweight and Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Low-fat cookies, interventions name: Watermelon, outcomesModule primaryOutcomes measure: Change of sexual health questionnaire scores, primaryOutcomes measure: Change of skin hydration scores, primaryOutcomes measure: Change of microbiome diversity, secondaryOutcomes measure: Change of depression questionnaire scores, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: School of Exercise and Nutritional Sciences, status: RECRUITING, city: San Diego, state: California, zip: 92182, country: United States, contacts name: Mee Young Hong, PhD, role: CONTACT, phone: 619-594-2392, email: mhong2@sdsu.edu, geoPoint lat: 32.71533, lon: -117.15726, hasResults: False
protocolSection identificationModule nctId: NCT06323057, orgStudyIdInfo id: Pro2022000444_CLFMT, briefTitle: Modulating Reward Learning Using Transcranial Magnetic Stimulation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-14, primaryCompletionDateStruct date: 2025-04-30, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Rutgers, The State University of New Jersey, class: OTHER, descriptionModule briefSummary: Our specific aim is to examine the effects of TMS on reward processing during goal-directed behavior. In these experiments the investigators will utilize a scalp-recorded brain oscillation called frontal midline theta that is believed to index the sensitivity of the cingulate cortex to reward feedback. Here the investigators will asked whether this electrophysiological signal can be modulated up or down using TMS while participants engage in decision making tasks, and if so, whether it would affect the encoding of rewards and subsequent choices during task performance., conditionsModule conditions: Behavior, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, maskingDescription: Participants will be blinded to the TMS condition (active or sham), whoMasked: PARTICIPANT, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: Single pulse TMS to the frontal cortex, outcomesModule primaryOutcomes measure: Event-related Brain Oscillation: Frontal Midline Theta, primaryOutcomes measure: Reward learning, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Rutgers University - Newark, status: RECRUITING, city: Newark, state: New Jersey, zip: 07102, country: United States, contacts name: Travis E Baker, PhD, role: CONTACT, phone: 862-250-3351, email: travis.e.baker@rutgers.edu, contacts name: Daniel Robles, PhD, role: CONTACT, phone: 973-353-3509, email: dr1147@newark.rutgers.edu, geoPoint lat: 40.73566, lon: -74.17237, hasResults: False
protocolSection identificationModule nctId: NCT06323044, orgStudyIdInfo id: I-3920723, secondaryIdInfos id: NCI-2024-01734, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: I-3920723, type: OTHER, domain: Roswell Park Cancer Institute, secondaryIdInfos id: R01CA283501, type: NIH, link: https://reporter.nih.gov/quickSearch/R01CA283501, briefTitle: MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-15, primaryCompletionDateStruct date: 2029-06-15, completionDateStruct date: 2029-06-15, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Roswell Park Cancer Institute, class: OTHER, descriptionModule briefSummary: This clinical trial identifies and addresses barriers to pediatric medication adherence among families of children with acute lymphoblastic leukemia. Pediatric nonadherence (noncompliance) to medication is a significant public health problem, and rigorous research repeatedly documents that nonadherence increases risk for hospitalization, healthcare cost, disease progression, and death. Pediatric acute lymphoblastic leukemia (ALL) patients who miss 5% of 6-mercaptopurine (6-MP) doses within the 2-year 6-MP regimen have a 2.7-fold risk of cancer that comes back after a period of improvement (relapse). To address these families' needs, researchers have developed MedSupport, a theory-based multilevel intervention with targets at the organizational, healthcare team, and caregiver levels that is designed to address root barriers to medication adherence. This study is being done to better understand families' experiences giving their child oral chemotherapy at home and to help families cope with the day-to-day challenges of giving their child medication., conditionsModule conditions: Acute Lymphoblastic Leukemia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Best Practice, interventions name: Biospecimen Collection, interventions name: Electronic Health Record Review, interventions name: Interview, interventions name: Medical Device Usage and Evaluation, interventions name: Medical Device Usage and Evaluation, interventions name: Survey Administration, outcomesModule primaryOutcomes measure: Medication adherence, eligibilityModule sex: ALL, minimumAge: 365 Days, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Roswell Park Cancer Institute, city: Buffalo, state: New York, zip: 14263, country: United States, contacts name: Kara M. Kelly, role: CONTACT, phone: 716-845-2333, email: Kara.Kelly@RoswellPark.org, contacts name: Kara M. Kelly, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.88645, lon: -78.87837, hasResults: False
protocolSection identificationModule nctId: NCT06323018, orgStudyIdInfo id: 384T-26, briefTitle: Effects of Remote Ischaemic Preconditioning in Cemented Hip Arthroplasty., acronym: PRINCIPAL, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: University of Tartu, class: OTHER, descriptionModule briefSummary: Total joint arthroplasty is one of the best treatment options for end-stage osteoarthritis. Cemented hip arthroplasty is mainly indicated for elderly patients with poor bone quality and multiple comorbidities. Bone cement implantation syndrome is associated with cemented hip arthroplasty and it has been shown to increase cardiovascular and renal complication and brain damage postoperatively. The aim of this project is to elucidate whether remote-ischemic preconditioning (RIPC) has multi-organ protective effect in cemented hip arthroplasty patients., conditionsModule conditions: Osteoarthritis, Hip, conditions: Cardiovascular Diseases, conditions: Bone Cement Implantation Syndrome, conditions: Kidney Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, maskingDescription: Randomization and intervention is done by a dedicated study nurse. Patient, orthopedic surgeon, investigator and outcomes assessor and statistician are all blinded to the study intervention., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Remote Ischemic Preconditioning, interventions name: SHAM, outcomesModule primaryOutcomes measure: Myocardial injury, secondaryOutcomes measure: Cardiovascular injury, secondaryOutcomes measure: Clinical serious complications, secondaryOutcomes measure: Carotid-femoral pulse velocity, secondaryOutcomes measure: Augmentation index, secondaryOutcomes measure: Brain injury, secondaryOutcomes measure: Kidney Injury, secondaryOutcomes measure: Total antioxidative capacity (TAC), secondaryOutcomes measure: Oxidative stress level (total peroxide levels), secondaryOutcomes measure: Inflammation level, secondaryOutcomes measure: Low molecular weight metabolites (uM), eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 90 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Tartu, status: RECRUITING, city: Tartu, state: Tartumaa, zip: 50406, country: Estonia, contacts name: Kaspar Tootsi, MD, PhD, role: CONTACT, phone: +3727318282, email: kaspar.tootsi@kliinikum.ee, geoPoint lat: 58.38062, lon: 26.72509, hasResults: False
protocolSection identificationModule nctId: NCT06323005, orgStudyIdInfo id: 2024-0024, briefTitle: [Trial of device that is not approved or cleared by the U.S. FDA], statusModule overallStatus: WITHHELD, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: [Redacted], hasResults: False
protocolSection identificationModule nctId: NCT06322992, orgStudyIdInfo id: R41CA271962, type: NIH, link: https://reporter.nih.gov/quickSearch/R41CA271962, briefTitle: App-Assisted Day Reconstruction to Reduce Treatment Burden and Logistic Toxicity in Cancer Patients - Aim 3, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Daynamica, Inc., class: INDUSTRY, collaborators name: Masonic Cancer Center, University of Minnesota, descriptionModule briefSummary: The goal of this observational study is to develop a mobile app for cancer patients undergoing treatments. In Aim 3, patients will rate the quality of the app using the Mobile App Rating Scale (MARS) and their satisfaction with the three key app features. The outcome of this project will be a final prototype app with 70% of patients indicating an overall MARS score of 4.0 or more and satisfaction with the three features., conditionsModule conditions: Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: APP satisfaction, primaryOutcomes measure: APP rating, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06322979, orgStudyIdInfo id: # R-PED-11-23-3074, briefTitle: Premixed Bioceramic Putty as an Apical Plug in Immature Anterior Permanent Teeth, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-22, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: Following the randomization procedure, children will be divided into 2 groups (25 immature anterior permanent incisors in each group): Group I will be treated with MTA as apical plug while group II will be treated with Premixed Bioceramic Putty as apical plug. After working length determination, instrumentation, and irrigation of the root canals, apical plug will be done. in MTA Group, MTA will be placed into the apical 4 mm of root canals, then a moist cotton pellet will be placed and the access cavity will be restored with glass-ionomer-based restoration. Next day, glass-ionomer-based restoration and the cotton pellet will be removed, then the coronal restoration will be completed with GIC, composite. In the Premixed Bioceramic Putty group, Well-Root™ PT will be placed into the apical 4 mm of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha. The coronal restoration will be completed with GIC, composite.children will be recalled for clinical and radiographical follow-up after 6 and12 months after treatment., conditionsModule conditions: Periapical Periodontitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Mineral trioxide aggregate, interventions name: Premixed Bioceramic Putty, outcomesModule primaryOutcomes measure: the clinical success of apexification after using a new apical plug material (Premixed Bioceramic Putty ) compared to the widely used material (MTA), primaryOutcomes measure: the radiographic success of apexification after using a new apical plug material (Premixed Bioceramic Putty ) compared to the widely used material (MTA), secondaryOutcomes measure: Change in the periapical index (PAI), eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 11 Years, stdAges: CHILD, contactsLocationsModule locations facility: Tanta University, status: RECRUITING, city: Tanta, state: Gharbia, zip: 6624033, country: Egypt, contacts name: Shaimaa eldesouky, PhD, role: CONTACT, phone: 01008994242, email: shiamaaeldesouky@dent.tanta.edu.eg, contacts name: mohamed ghaly, PhD, role: CONTACT, phone: 01098472899, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06322927, orgStudyIdInfo id: CFTsp231, secondaryIdInfos id: 24_CPCR_38, type: OTHER, domain: ChristieNHS, briefTitle: PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma, acronym: iPREFER, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-31, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: The Christie NHS Foundation Trust, class: OTHER, collaborators name: CellCentric Ltd., descriptionModule briefSummary: This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to them when making treatment decisions., conditionsModule conditions: Multiple Myeloma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Patient Interview, outcomesModule primaryOutcomes measure: Patient Experience and Preference, secondaryOutcomes measure: Treatment and Preference Differences, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Christie NHS Foundation Trust, city: Manchester, state: Greater Manchester, zip: M20 4BX, country: United Kingdom, geoPoint lat: 53.48095, lon: -2.23743, hasResults: False
protocolSection identificationModule nctId: NCT06322914, orgStudyIdInfo id: 029, briefTitle: A Novel Scoring System for Predicting the Success of PCI in Patients With CTO, statusModule overallStatus: COMPLETED, startDateStruct date: 2012-01, primaryCompletionDateStruct date: 2023-11, completionDateStruct date: 2023-11, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: The investigators conducted a retrospective, single-center observational registry upon which one novel scoring system was formed and evaluated for their accuracy in predicting technical success. The investigators reviewed the clinical and angiographic records of 432 patients with 459 CTO lesions who underwent percutaneous recanalization attempts recruited between January 2012 and November 2023. The investigators aims to develop and validate a novel scoring system for predicting CTO-PCI success., conditionsModule conditions: Chronic Total Occlusion (CTO), designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 493, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: PCI technical success, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: First Affiliated Hospital of Nanjing Medical University, city: Nanjing, state: Jiangsu, zip: 210029, country: China, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06322901, orgStudyIdInfo id: TDH-2018-7883, briefTitle: The Effect Of Vertical Releasing Incision On Implant Procedures, acronym: Vertikal, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-08-05, primaryCompletionDateStruct date: 2020-10-02, completionDateStruct date: 2020-10-02, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: TC Erciyes University, class: OTHER, descriptionModule briefSummary: This study evaluated the clinical and biochemical aspects of flap design in dental implant applications regarding implantation success and patient comfort. In this split-mouth randomized controlled clinical trial, a vertical releasing incision was made at the distal end of the crestal incision on the test side, and the control side received a crestal incision alone. Sixty-eight implants were placed in 17 patients. Peri-implant groove fluid was collected on postsurgical days 3, 7, 30, and 90; OPG and RANKL levels were assessed to determine bone formation and resorption around the implants. Cortisol levels were assessed in peri-implant groove fluid at postsurgical days 3, 7, and 14. Visual analog scale (VAS), and swelling measurements were taken postoperatively. Panoramic and periapical X-rays were obtained immediately post-surgery and at 3 months. No significant marginal bone loss difference was observed between the test and control sides at 3 months. The RANKL/OPG ratio, cortisol levels, VAS scores, and swelling scores were higher in the test vs. control sides. Overall, while the use of a vertical incision has advantages, such as increasing the visual field of the surgeon and improving the ease of the operation, this approach should be used only when necessary, given the disadvantages of increased bone resorption mediators in the peri-implant tissue and reduced postoperative patient comfort., conditionsModule conditions: Bone Loss, conditions: Flap Design, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 17, type: ACTUAL, armsInterventionsModule interventions name: Flap, outcomesModule primaryOutcomes measure: Bone loss, otherOutcomes measure: OPG/RANKL, otherOutcomes measure: visual analog scale (VAS), otherOutcomes measure: cortisol levels, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erciyes University Faculty of Dentistry, city: Melikgazi, state: Kayseri, zip: 38039, country: Turkey, hasResults: False
protocolSection identificationModule nctId: NCT06322875, orgStudyIdInfo id: SKCCOL002, briefTitle: A Clinical Study to Evaluate the Efficacy and Satisfaction of RHC Serum Combined With RHC(III) Injection, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: DeYi Aesthetic Medical Clinic, class: OTHER, descriptionModule briefSummary: To evaluate the efficacy and safety of recombinant humanized collagen (type III) solution for injection combined with SkinCeuticals recombinant humanized collagen (RHC) serum Participants will be assessed by subjective questionnaire (FACE-Q Satisfaction with skin,Global Aesthetic Improvement Scale, et al) and some medical instruments (VISIA,Ultrascan UC22 et al), conditionsModule conditions: Facial Wrinkles, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule interventions name: Recombinant type III humanized collagen solution for injection, interventions name: SkinCeuticals recombinant humanized collagen (RHC) serum, interventions name: Regular face cream smear, outcomesModule primaryOutcomes measure: FACE-Q Satisfaction with skin, secondaryOutcomes measure: Investigator Global Aesthetic Improvement Scale (I-GAIS) Rates, secondaryOutcomes measure: Subject Global Aesthetic Improvement Scale (S-GAIS) Rates, secondaryOutcomes measure: Improvement rate assessed by Atlas, secondaryOutcomes measure: Change in Cutometer® dual Analysis Score, secondaryOutcomes measure: Change in VISIA® Skin Analysis Score, secondaryOutcomes measure: FACE-Q Satisfaction with Outcome, secondaryOutcomes measure: FACE-Q Satisfaction with skin, secondaryOutcomes measure: Change of the thickness and density of subjects' facial dermis, otherOutcomes measure: Changes from baseline in skin uniformity and spot area ratio measurements collected by VISIA's face image acquisition instrument., eligibilityModule sex: FEMALE, minimumAge: 30 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False